ACR/ARHP 2016 Annual Meeting
Tofacitinib Effective in PsA Patients With Prior Inadequate Response
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
Your search for tofacitinib returned 2 results
EULAR 2017
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
